Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly four years after vaccination, patients’ immune cells were still active against their cancer.
COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.
Social media posts that make misleading comparisons undermine the science behind the COVID-19 vaccine.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
Most vaccines can be administered on a flexible timeline if the originally recommended timeline is missed.
Combining a custom cancer vaccine and a checkpoint inhibitor generated tumor-specific immune responses in a majority of patients.
Psychologist Seth Axelrod, PhD, has metastatic bone cancer—and a unique set of therapeutic skills that help him live with it.
We’re all familiar with vaccines that prime the immune system to prevent infections. Can a similar approach be used to fight cancer?
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
The biological mechanisms responsible for the abscopal effect are still being investigated, but the immune system may play an big role.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
In fact, there are even types of vaccines, known simply as cancer vaccines, that can prevent or potentially treat cancer.
“The simplicity of this approach means that it is promising to take forward” to a human vaccine, researchers say.
Many vaccines are preventive. This is a THERAPEUTIC vaccine: it teaches your immune system to recognize the problem AFTER you have it.
The vaccine, based on an individual’s own tumor cells, improved survival time and proved safe in an early-stage trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.